Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
CorMedix Is Maintained at Outperform by RBC Capital
Cormedix Analyst Ratings
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix Analyst Ratings
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $18
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Cormedix (CRMD) Receives a Buy From Truist Financial
CorMedix Is Maintained at Buy by Truist Securities
Cormedix Analyst Ratings
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Cormedix (CRMD) Receives a Buy From JMP Securities
Buy Rating on Cormedix Affirmed Amidst DefenCath's Strong Market Entry and Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19